Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer
Monitoring and Timely Intervention of Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients: A Multicenter, Randomized, Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jianyong Lei, MD
- Phone Number: 86-19983137992
- Email: leijianyong@scu.edu.cn
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital
-
Contact:
- Jianyong Lei, MD
- Phone Number: 86-19983137992
- Email: leijianyong@scu.edu.cn
-
Contact:
- Ziyang Ye, Dr
- Phone Number: 86-16605758778
-
Sub-Investigator:
- Ziyang Ye, Dr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with low-risk papillary thyroid cancer without lymph node metastasis who have undergone thyroid surgery,
- Aged between 18 and 90 years,
- Chinese-speaking,
- Capable of completing questionnaires and using a mobile phone and internet for intervention purposes,
- No history of psychiatric disorders or use of psychotropic medications,
- Voluntary participation and signing of an informed consent form.
Exclusion Criteria:
- Patients with cervical lymph node metastasis,
- Incomplete baseline data,
- Uncontrolled chronic diseases,
- Patients with other cancers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervening in patients with postoperative regret emotion.
For the worst postoperative quality of life factors reported by patients, specialized doctors will provide immediate guidance and management via SMS or phone.
|
Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.
|
|
No Intervention: Only the patients' postoperative regret levels and quality of life scores will be collected.
Only the patients' postoperative regret levels and quality of life scores will be collected, without any additional interventions.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clarifying the impact of immediate intervention on patients' postoperative regret psychology.
Time Frame: From enrollment to the end of follow-up at 12 months
|
Over a 12-month period after the start of the study, observe the declining trend of regret scores in patients who received immediate intervention compared to the control group.
|
From enrollment to the end of follow-up at 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Main Factors Affecting Postoperative Regret in Low-Risk PTC Patients
Time Frame: From enrollment to the end of follow-up at 12 months
|
Over a 12-month period after the start of the study, evaluate patients' quality of life in different aspects following thyroid cancer surgery at each time point using the thyroid cancer-specific Quality of Life (QoL) scale.
|
From enrollment to the end of follow-up at 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WestChinaH20220423
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer
-
NCT00095693TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid Cancer
-
NCT01413113CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer
-
NCT06458036RecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, Thyroid
-
NCT00085293CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer
-
NCT00104871CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer
-
NCT00654238CompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid Cancer
-
NCT05783323RecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, Thyroid
-
NCT03630120TerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer
-
NCT00098813CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer
-
NCT01723202CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Papillary Thyroid Cancer | Follicular Thyroid Cancer
Clinical Trials on Postoperative Regret Reduction through Immediate Quality of Life Intervention
-
NCT03258892Completed
-
NCT05213078CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Female Reproductive System Neoplasm
-
NCT03775616CompletedCaregiver | Solid Neoplasm
-
NCT03804164WithdrawnHematopoietic and Lymphoid Cell Neoplasm
-
NCT03751449TerminatedObesity | Overweight | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8
-
NCT05054296RecruitingBiochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma
-
NCT02408406CompletedBreast Carcinoma | Lung Carcinoma | Colorectal Carcinoma | Malignant Neoplasm | Bladder Carcinoma | Malignant Female Reproductive System Neoplasm
-
NCT03568526CompletedPeripheral Neuropathy | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7
-
NCT01641068CompletedBreast Carcinoma | Cancer Survivor | Malignant Female Reproductive System Neoplasm | Cognitive Side Effects of Cancer Therapy
-
NCT00958698UnknownRecurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Psychological Impact of Cancer